5-[(3,6-二氢-4-苯基-1(2H)-吡啶基)甲基]-2-甲基-4-嘧啶胺二盐酸盐 | 189744-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-[(3,6-二氢-4-苯基-1(2H)-吡啶基)甲基]-2-甲基-4-嘧啶胺二盐酸盐
• 英文名称: Ro 10-5824 dihydrochloride
• 英文别名: 2-methyl-5-[(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methyl]pyrimidin-4-amine;dihydrochloride
• CAS: 189744-94-3
• 化学式: C17H22Cl2N4
• 分子量: 353.3
• InChiKey: UZHMRJRDYCRKIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  55
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] PYRIMIDIN DERIVATIVES<br/>[FR] DERIVES DE PYRIMIDINE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1997013759A1

  公开（公告）日：1997-04-17

  (EN) The invention is concerned with compounds of general formula (I), wherein R1 and R2 each individually signify lower-alkyl or amino, A signifies A1, A2, A3, A4, A5, A6 or A7; B signifies hydrogen in A4, A5 and A6; (i) in A1-A6; lower-alkoxy in A4-A6; and lower alkyl, styryl, phenylethynyl or benzoyloxy-lower-alkyl in A1 and A2; n signifies 0-2; m, p signify 0, 1 and R3, R4, R5 and R6 each independently signify hydrogen, halogen, lower-alkyl, trifluoromethyl, lower-alkoxy or nitro, and pharmaceutically acceptable acid addition salts thereof. These compounds can be used in the control or prevention of illnesses which are caused by disorders of the dopamine system. Psychotic illnesses such as e.g. schizophrenia belong to these.(FR) L'invention concerne des composés de la formule générale (I), ainsi que des sels d'addition d'acide de ceux-ci, acceptables sur le plan pharmacologique. Dans cette formule, R1 et R2 représentent chacun individuellement alkyle inférieur ou amino, A représente A1, A2, A3, A4, A5, A6 ou A7; B représente hydrogène dans A4, A5 et A6, (i) dans A1-A6, alcoxy inférieur dans A4-A6, et alkyle inférieur, styryle, phényléthynyle ou benzoyloxy-alkyle inférieur dans A1 et A2; n vaut 0-2; m, p valent 0, 1 et R3, R4, R5 et R6 représentent chacun indépendamment hydrogène, halogène, alkyle inférieur, trifluorométhyle, alcoxy inférieur ou nitro. On peut utiliser ces composés dans la lutte contre certaines maladies, ou dans la prévention de celles-ci, lesquelles sont provoquées par des troubles du système dopaminergique. Des maladies psychotiques, telles que par exemple la schizophrénie, appartiennent à ces maladies.

  该发明涉及通式（I）的化合物，其中R1和R2各自表示较低的烷基或氨基，A表示A1，A2，A3，A4，A5，A6或A7; B在A4，A5和A6中表示氢，（i）在A1-A6中表示较低的烷氧基，在A4-A6中表示较低的烷氧基，在A1和A2中表示较低的烷基，苯乙烯基，苯乙炔基或苯甲酰氧基-较低的烷基； n表示0-2; m，p表示0，1，R3，R4，R5和R6各自独立地表示氢，卤素，较低的烷基，三氟甲基，较低的烷氧基或硝基，以及其药学上可接受的酸加合物盐。这些化合物可用于控制或预防由多巴胺系统障碍引起的疾病。精神疾病，例如精神分裂症属于这些疾病。
• Mouse with D4R iRNA in the intercalating cell mass of the amygdala
  申请人：POSTECH ACADEMY-INDUSTRY FOUNDATION

  公开号：US10668061B2

  公开（公告）日：2020-06-02

  Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.

  本发明提供了一种多巴胺受体亚型4（D4R）受损或缺乏的创伤后应激障碍（PTSD）动物模型、一种制备该动物模型的方法、一种利用该动物模型筛选治疗PTSD药物的方法，以及一种治疗PTSD的药物组合物，该药物组合物包含通过该筛选方法检测到的药物。由于确定了特定类型的多巴胺受体与长期抑郁（LTD）诱导的恐惧记忆表达机制有关，因此可以加深对创伤后应激障碍发病机制的理解，表现出类似创伤后应激障碍临床症状的动物模型及其制备方法可用于分析创伤后应激障碍治疗剂的稳定性和有效性以及筛选治疗药物。此外，本发明组合物中所含的一种D4R的激动剂已被美国FDA批准并用于精神分裂症等精神疾病的临床治疗，因此可立即用于创伤后应激障碍症状的临床应用。
• PYRIMIDIN DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0873317B1

  公开（公告）日：2001-04-11
• PHARMACEUTICAL COMPOSITION FOR TREATING POSTTRAUMATIC STRESS DISORDER
  申请人：POSTECH ACADEMY-INDUSTRY FOUNDATION

  公开号：US20180064707A1

  公开（公告）日：2018-03-08

  Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.
• US5688798A
  申请人：——

  公开号：US5688798A

  公开（公告）日：1997-11-18